CN111454290B - 卡比多巴和左旋多巴前药及它们治疗帕金森病的用途 - Google Patents

卡比多巴和左旋多巴前药及它们治疗帕金森病的用途 Download PDF

Info

Publication number
CN111454290B
CN111454290B CN202010250046.4A CN202010250046A CN111454290B CN 111454290 B CN111454290 B CN 111454290B CN 202010250046 A CN202010250046 A CN 202010250046A CN 111454290 B CN111454290 B CN 111454290B
Authority
CN
China
Prior art keywords
compound
levodopa
formula
carbidopa
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010250046.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN111454290A (zh
Inventor
B.卡迪纳尔-戴维
V.S.陈
K.E.邓帕
B.P.恩赖特
R.F.亨利
R.候
黄冶
A.D.哈特斯
R.C.克利克斯
S.W.克拉布
P.R.凯姆
劳彦斌
娄晓春
S.E.麦基
M.A.马图伦科
P.T.迈尔
C.P.米勒
J.斯坦布利
E.A.沃伊特
Z.王
张光中
V.J.斯特拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN111454290(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of CN111454290A publication Critical patent/CN111454290A/zh
Application granted granted Critical
Publication of CN111454290B publication Critical patent/CN111454290B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202010250046.4A 2014-10-21 2015-10-21 卡比多巴和左旋多巴前药及它们治疗帕金森病的用途 Active CN111454290B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462066771P 2014-10-21 2014-10-21
US62/066771 2014-10-21
CN201580069519.8A CN107206013A (zh) 2014-10-21 2015-10-21 卡比多巴和左旋多巴前药及它们治疗帕金森病的用途
PCT/US2015/056686 WO2016065019A1 (en) 2014-10-21 2015-10-21 Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580069519.8A Division CN107206013A (zh) 2014-10-21 2015-10-21 卡比多巴和左旋多巴前药及它们治疗帕金森病的用途

Publications (2)

Publication Number Publication Date
CN111454290A CN111454290A (zh) 2020-07-28
CN111454290B true CN111454290B (zh) 2022-12-23

Family

ID=54478240

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202010250046.4A Active CN111454290B (zh) 2014-10-21 2015-10-21 卡比多巴和左旋多巴前药及它们治疗帕金森病的用途
CN202010123543.8A Active CN111362980B (zh) 2014-10-21 2015-10-21 卡比多巴和左旋多巴前药及它们治疗帕金森病的用途
CN201580069519.8A Pending CN107206013A (zh) 2014-10-21 2015-10-21 卡比多巴和左旋多巴前药及它们治疗帕金森病的用途
CN202010250040.7A Active CN111494395B (zh) 2014-10-21 2015-10-21 卡比多巴和左旋多巴前药及它们治疗帕金森病的用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202010123543.8A Active CN111362980B (zh) 2014-10-21 2015-10-21 卡比多巴和左旋多巴前药及它们治疗帕金森病的用途
CN201580069519.8A Pending CN107206013A (zh) 2014-10-21 2015-10-21 卡比多巴和左旋多巴前药及它们治疗帕金森病的用途
CN202010250040.7A Active CN111494395B (zh) 2014-10-21 2015-10-21 卡比多巴和左旋多巴前药及它们治疗帕金森病的用途

Country Status (37)

Country Link
US (7) US9446059B2 (enExample)
EP (3) EP3569587A1 (enExample)
JP (6) JP6567049B2 (enExample)
KR (3) KR20240113982A (enExample)
CN (4) CN111454290B (enExample)
AR (1) AR102389A1 (enExample)
AU (4) AU2015335941B2 (enExample)
BR (1) BR112017008198B1 (enExample)
CA (1) CA2965379A1 (enExample)
CY (2) CY1121826T1 (enExample)
DK (1) DK3209302T3 (enExample)
ES (1) ES2739536T3 (enExample)
FI (1) FIC20230014I1 (enExample)
FR (1) FR23C1035I2 (enExample)
HR (1) HRP20191285T1 (enExample)
HU (2) HUE044115T2 (enExample)
IL (3) IL251829B (enExample)
LT (2) LT3209302T (enExample)
LU (1) LUC00304I2 (enExample)
MX (2) MX393568B (enExample)
MY (1) MY189519A (enExample)
NL (1) NL301224I2 (enExample)
NO (1) NO2023013I1 (enExample)
PH (1) PH12017500746B1 (enExample)
PL (1) PL3209302T3 (enExample)
PT (1) PT3209302T (enExample)
RS (1) RS58972B1 (enExample)
RU (2) RU2743347C2 (enExample)
SA (1) SA521421115B1 (enExample)
SG (1) SG11201703170RA (enExample)
SI (1) SI3209302T1 (enExample)
SM (1) SMT201900376T1 (enExample)
TR (1) TR201908296T4 (enExample)
TW (2) TWI718999B (enExample)
UA (1) UA120437C2 (enExample)
WO (1) WO2016065019A1 (enExample)
ZA (1) ZA201702760B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3777833T3 (pl) 2014-03-13 2024-03-25 Neuroderm Ltd. Kompozycje inhibitorów dekarboksylazy dopa
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
RS58972B1 (sr) 2014-10-21 2019-08-30 Abbvie Inc Karbidopa i l-dopa prolekovi i njihova primena za lečenje parkinsonove bolesti
EP4295909A3 (en) * 2016-04-20 2024-07-17 AbbVie Inc. Carbidopa and l-dopa prodrugs and methods of use
US11148999B2 (en) 2016-06-22 2021-10-19 MedChem Partners, LLC Nitric oxide donors
WO2018154447A1 (en) * 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US20180311238A1 (en) * 2017-04-28 2018-11-01 Saniona A/S Selective Agonist Of a6 Containing nAChRs
WO2019097120A1 (en) 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
MX2020005366A (es) 2017-11-24 2020-08-13 H Lundbeck As Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
CN110294789A (zh) * 2018-03-21 2019-10-01 海南大学 含多巴寡肽的合成方法及其在抗帕金森病前药方面的应用
AU2019338938B2 (en) 2018-09-13 2023-01-19 University Of Canberra Methods of inhibition
EP3880210A1 (en) * 2018-11-15 2021-09-22 Abbvie Inc. Pharmaceutical formulations for subcutaneous administration
WO2020178810A1 (en) * 2019-03-04 2020-09-10 Neuroderm, Ltd. Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
CN113727712B (zh) 2019-05-21 2024-11-15 H.隆德贝克有限公司 用于治疗帕金森病的儿茶酚胺氨基甲酸酯前药
CN113677675B (zh) 2019-05-21 2024-07-26 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
CN113727979B (zh) 2019-05-21 2024-09-20 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
CN119707810A (zh) 2019-05-21 2025-03-28 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
EP4223288B1 (en) 2022-02-07 2024-03-06 Berlirem GmbH Novel kit of pharmaceutical preparations for the treatment of parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) * 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4508706A (en) * 1983-03-30 1985-04-02 Yale University Composition for increasing melanin in mammalian skin and hair
US5073547A (en) * 1989-04-20 1991-12-17 Simes Societa Italiana Medicinali E Sintetici S.P.A. Dopamine pro-drug
US6576766B1 (en) * 1997-11-12 2003-06-10 Ariad Pharmaceuticals, Inc. Signal transduction inhibitors, compositions containing them
CN1845728A (zh) * 2003-08-29 2006-10-11 转化医药公司 药物组合物和使用左旋多巴和卡比多巴的方法
CN111362980A (zh) * 2014-10-21 2020-07-03 艾伯维公司 卡比多巴和左旋多巴前药及它们治疗帕金森病的用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016288A (en) * 1975-08-13 1977-04-05 Merck & Co., Inc. Compositions and method of treating hypertension
DD230865B1 (de) * 1982-08-09 1987-05-20 Dresden Arzneimittel Verfahren zur herstellung von hydrazinocarbonsaeurederivaten durch n-aminierung von aminocarbonsaeurederivaten
US4618484A (en) 1983-03-30 1986-10-21 Yale University Composition and method for treatment of melanomas
IT1213182B (it) * 1984-06-25 1989-12-14 Simes Derivati di composti a struttura catecolamminica.
US4616484A (en) 1984-11-30 1986-10-14 Kysor Industrial Corporation Vehicle refrigerant heating and cooling system
IT1200427B (it) 1985-03-22 1989-01-18 Afros Spa Procedimento ed impianto per lo stampaggio di pezzi in materiale plastico espanso,con parti o inserti preformati a spruzzo nello stesso stampo di formatura
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
GB9102812D0 (en) 1991-02-11 1991-03-27 Enzymatix Ltd Compounds
IT1255471B (it) 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
KR20050016449A (ko) * 2002-05-29 2005-02-21 임팩스 라보라토리즈, 인코포레이티드 레보도파/카르비도파의 즉시 방출 및 제어 방출 조합 투여형
CA2490626A1 (en) 2002-06-20 2003-12-31 Nippon Suisan Kaisha, Ltd. Prodrug, medicinal utilization thereof and process for producing the same
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
WO2004069146A2 (en) 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
EP1670450B8 (en) 2003-08-29 2011-03-23 Centocor Ortho Biotech Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
CA2543945A1 (en) 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid
MX339690B (es) * 2004-06-04 2016-06-06 Xenoport Inc Profarmacos de levodopa y sus composiciones y usos.
KR101229431B1 (ko) 2004-07-06 2013-02-04 아보트 러보러터리즈 Ｈｉｖ 프로테아제 억제제의 프로드럭
CA2631643C (en) * 2005-12-05 2015-07-07 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
WO2007138086A1 (en) * 2006-05-31 2007-12-06 Solvay Pharmaceuticals Gmbh Long term 24 hour intestinal administration of levodopa/carbidopa
JP2009539942A (ja) * 2006-06-16 2009-11-19 ソルベイ・フアーマシユーチカルズ・ベー・ブイ ビフェプルノックス及びｌ−ｄｏｐａを含む組み合わせ製剤
TW200843732A (en) 2006-12-21 2008-11-16 Xenoport Inc Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
GB0713189D0 (en) 2007-07-06 2007-08-15 Proximagen Ltd Amino acid derivatives
ATE510537T1 (de) * 2008-02-06 2011-06-15 Wockhardt Research Center Pharmazeutische zusammensetzungen von entacapon, levodopa und carbidopa mit verbesserter bioverfügbarkeit
AU2009249067A1 (en) 2008-05-20 2009-11-26 Neurogesx, Inc. Water-soluble acetaminophen analogs
PT2432454T (pt) 2009-05-19 2017-06-12 Neuroderm Ltd Composições para administração contínua de inibidores de dopa decarboxilase
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
WO2011056240A2 (en) 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
WO2011109767A2 (en) 2010-03-04 2011-09-09 University Of Notre Dame Du Lac Gelatinase inhibitors and prodrugs
SI2640358T1 (en) 2010-11-15 2018-05-31 Neuroderm Ltd. Continuous administration of L-dopa, dopamine decarboxylase inhibitors, catechol-O-methyl transferase inhibitors, and compositions thereof
CA2818161A1 (en) 2010-12-02 2012-06-07 Ono Pharmaceutical Co., Ltd. Novel compound and medical use thereof
US20140088192A1 (en) 2010-12-10 2014-03-27 Synagile Corporation Subcutaneously infusible levodopa prodrug compositions and methods of infusion
US8765189B2 (en) * 2011-05-13 2014-07-01 Howmedica Osteonic Corp. Organophosphorous and multivalent metal compound compositions and methods
KR20130070371A (ko) * 2011-12-19 2013-06-27 울산대학교 산학협력단 퇴행성 신경질환 예방 또는 치료용 조성물
EP2968218B1 (en) 2013-03-13 2021-07-07 Neuroderm Ltd Combination for the treatment of parkinson's disease
BR112015022896B1 (pt) 2013-03-15 2022-08-23 Chongxi Yu Composto de fármacos de alta penetração, composição farmacêutica e seus usos para o tratamento de doenças de parkinson
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
EP4295909A3 (en) 2016-04-20 2024-07-17 AbbVie Inc. Carbidopa and l-dopa prodrugs and methods of use
WO2018059739A1 (en) 2016-09-29 2018-04-05 Berlirem Gmbh L-dopa derivatives for the treatment of neurological diseases
WO2018154447A1 (en) 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) * 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4508706A (en) * 1983-03-30 1985-04-02 Yale University Composition for increasing melanin in mammalian skin and hair
US5073547A (en) * 1989-04-20 1991-12-17 Simes Societa Italiana Medicinali E Sintetici S.P.A. Dopamine pro-drug
US6576766B1 (en) * 1997-11-12 2003-06-10 Ariad Pharmaceuticals, Inc. Signal transduction inhibitors, compositions containing them
CN1845728A (zh) * 2003-08-29 2006-10-11 转化医药公司 药物组合物和使用左旋多巴和卡比多巴的方法
CN111362980A (zh) * 2014-10-21 2020-07-03 艾伯维公司 卡比多巴和左旋多巴前药及它们治疗帕金森病的用途

Also Published As

Publication number Publication date
AU2021201414B2 (en) 2023-05-11
EP4186510A1 (en) 2023-05-31
LT3209302T (lt) 2019-06-10
CN111494395B (zh) 2024-06-21
RU2743347C2 (ru) 2021-02-17
BR112017008198B1 (pt) 2021-02-09
TR201908296T4 (tr) 2019-06-21
MX2021003840A (es) 2022-06-30
JP6567049B2 (ja) 2019-08-28
KR20170071599A (ko) 2017-06-23
RU2017117413A3 (enExample) 2019-05-30
PL3209302T3 (pl) 2019-10-31
JP2021183628A (ja) 2021-12-02
NO2023013I1 (no) 2023-03-20
AU2015335941B2 (en) 2021-04-01
JP2020189864A (ja) 2020-11-26
CN111454290A (zh) 2020-07-28
US11091507B2 (en) 2021-08-17
SMT201900376T1 (it) 2019-09-09
NL301224I1 (enExample) 2023-03-29
WO2016065019A1 (en) 2016-04-28
RS58972B1 (sr) 2019-08-30
CY2023010I1 (el) 2023-06-09
HUE044115T2 (hu) 2019-10-28
AU2021201414A1 (en) 2021-03-25
US20180079762A1 (en) 2018-03-22
JP2019218356A (ja) 2019-12-26
CY1121826T1 (el) 2020-07-31
LUC00304I2 (enExample) 2025-09-22
PH12017500746B1 (en) 2021-12-15
IL251829A0 (en) 2017-06-29
US10174061B2 (en) 2019-01-08
SG11201703170RA (en) 2017-05-30
AU2015335941A1 (en) 2017-05-04
EP3569587A1 (en) 2019-11-20
MX381069B (es) 2025-03-12
MX2017005236A (es) 2017-07-26
SI3209302T1 (sl) 2019-06-28
LTC3209302I2 (enExample) 2025-10-10
CN107206013A (zh) 2017-09-26
BR112017008198A2 (pt) 2017-12-26
EP3209302B1 (en) 2019-04-24
HRP20191285T1 (hr) 2019-10-18
SA521421115B1 (ar) 2022-03-01
CA2965379A1 (en) 2016-04-28
US20190375770A1 (en) 2019-12-12
JP2017537066A (ja) 2017-12-14
AR102389A1 (es) 2017-02-22
US20220153765A1 (en) 2022-05-19
IL276493A (en) 2020-09-30
US10730895B2 (en) 2020-08-04
TW201630924A (zh) 2016-09-01
RU2017117413A (ru) 2018-11-26
FR23C1035I1 (fr) 2023-12-08
ES2739536T3 (es) 2020-01-31
DK3209302T3 (da) 2019-05-13
TW202131931A (zh) 2021-09-01
JP6932227B2 (ja) 2021-09-08
KR20230066484A (ko) 2023-05-15
JP6750076B2 (ja) 2020-09-02
CY2023010I2 (el) 2023-06-09
US20230106081A1 (en) 2023-04-06
US20200262852A1 (en) 2020-08-20
TWI718999B (zh) 2021-02-21
JP2025118978A (ja) 2025-08-13
CN111362980A (zh) 2020-07-03
AU2025238004A1 (en) 2025-10-16
IL251829B (en) 2019-09-26
ZA201702760B (en) 2022-05-25
KR102537018B1 (ko) 2023-05-30
KR20240113982A (ko) 2024-07-23
NZ769153A (en) 2024-04-26
TWI755257B (zh) 2022-02-11
PT3209302T (pt) 2019-07-19
FR23C1035I2 (fr) 2025-04-18
CN111362980B (zh) 2022-10-18
FIC20230014I1 (fi) 2023-03-31
JP2023174770A (ja) 2023-12-08
UA120437C2 (uk) 2019-12-10
JP7688087B2 (ja) 2025-06-03
MX393568B (es) 2025-03-24
LTPA2023519I1 (enExample) 2023-06-26
CN111494395A (zh) 2020-08-07
RU2021103000A (ru) 2021-03-01
IL268885B (en) 2020-08-31
MY189519A (en) 2022-02-16
IL268885A (en) 2019-10-31
PH12017500746A1 (en) 2017-10-30
US9446059B2 (en) 2016-09-20
HUS2300009I1 (hu) 2023-03-28
NL301224I2 (nl) 2023-08-16
US20160106765A1 (en) 2016-04-21
NZ730996A (en) 2024-04-26
US20160362431A1 (en) 2016-12-15
EP3209302A1 (en) 2017-08-30
AU2023210650A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
CN111454290B (zh) 卡比多巴和左旋多巴前药及它们治疗帕金森病的用途
US20240024338A1 (en) Carbidopa and l-dopa prodrugs and methods of use
HK40034110A (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
HK40034110B (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
HK40092679A (en) Intermediates and process for preparing l-dopa diphosphate
HK40017405A (en) Intermediates and process for preparing l-dopa diphosphate
HK1240507B (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
HK1240507A1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40034110

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant